The documents, marked sensitive and not intended for public disclosure, circulated widely across intelligence offices, law-enforcement agencies, and federal drug task forces throughout the year. Again and again, they flag unresolved questions about TdA’s US footprint, including its size, financing, and weapons access, warning that key estimates—such as the number of members operating in the US—were often inferred or extrapolated by analysts due to a lack of corroborated facts.